AstraZeneca posts L-MOCA olaparib results; CKD retinal imaging study not yet recruiting
AstraZeneca's L-MOCA olaparib maintenance study posted results after completion, while a separate retinal imaging study for chronic kidney disease has not yet started recruiting.
AstraZeneca had one completed trial with new results and one collaborator-sponsored study that has not yet begun enrolling.
- L-MOCA (NCT03534453), a Phase 3 single-arm study of olaparib tablets as maintenance monotherapy in platinum sensitive relapsed ovarian cancer, is listed as completed with results first posted on 2026-11-16. The study assessed olaparib maintenance monotherapy in patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in complete or partial response to platinum-based chemotherapy.1 The study enrolled 225 participants.1
- A validation study of a machine-learning algorithm using digital retinal images to predict chronic kidney disease (NCT07940205) is not yet recruiting, with an estimated start date of 2027-01-01. The study is sponsored by Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI), with AstraZeneca listed as a collaborator. The non-interventional study aims to validate the algorithm's performance in predicting eGFR from retinal images for potential use as a population-based screening tool.2 It plans to enroll 500 participants, including 350 cases with diabetes and/or hypertension and/or CKD.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.